[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100620389":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":30,"locations":36,"responsibleParty":83,"collaborators":86,"id":92,"slug":93,"hasResults":94,"nctId":95,"briefTitle":96,"officialTitle":96,"acronym":97,"eligibilityCriteria":98,"healthyVolunteers":94,"sex":99,"minAge":100,"maxAge":10,"enrollmentInfo":101,"targetDuration":10,"studyType":104,"phases":10,"briefSummary":105,"conditions":106,"keywords":109,"overallStatus":112,"whyStopped":10,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":122},{"fullName":5,"class":6},"Oregon Health and Science University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Postpartum Stelo Users",null,"Postpartum individuals with their most recent pregnancy complicated by Gestational Diabetes Mellitus (GDM)",[13],"Device: Dexcom Stelo real-time Continuous Glucose Monitor",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"DEVICE","Dexcom Stelo real-time Continuous Glucose Monitor","The Stelo Glucose Biosensor is an over-the-counter integrated Continuous Glucose Monitor (iCGM) intended to continuously measure, record, analyze, and display glucose values in people 18 years and older not on insulin. Participants will use Stelo for the 6 weeks following delivery and for 15 days at 3 months, 6 months, 9 months, and 1 year postpartum.",[9],[21,24,27],{"name":22,"affiliation":5,"role":23},"Amy M Valent, DO, MCR","PRINCIPAL_INVESTIGATOR",{"name":25,"affiliation":26,"role":23},"Celeste Durnwald, MD","University of Pennsylvania",{"name":28,"affiliation":29,"role":23},"Kristin Castorino, DO","Sansum Diabetes Research Institute",[31],{"name":32,"role":33,"phone":34,"phoneExt":10,"email":35},"Christian Huertas Pagan","CONTACT","503-418-1231","mfmresearch@ohsu.edu",[37,55,68],{"facility":29,"status":10,"city":38,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"Santa Barbara","California","93105","United States","US",{"type":44,"coordinates":45},"Point",[46,47],-119.69819,34.42083,{"lat":47,"lon":46},[50,54],{"name":51,"role":33,"phone":52,"phoneExt":10,"email":53},"Alex AlChwikani, Recruitment Specialist","805-682-7640","Aalchwikani@sansum.org",{"name":28,"role":23,"phone":10,"phoneExt":10,"email":10},{"facility":56,"status":10,"city":57,"state":58,"zip":59,"country":41,"countryCode":42,"cosmosGeoPoint":60,"geoPoint":64,"contacts":65},"Oregon Health & Science University","Portland","Oregon","97239",{"type":44,"coordinates":61},[62,63],-122.67621,45.52345,{"lat":63,"lon":62},[66,67],{"name":32,"role":33,"phone":34,"phoneExt":10,"email":35},{"name":22,"role":23,"phone":10,"phoneExt":10,"email":10},{"facility":26,"status":10,"city":69,"state":70,"zip":71,"country":41,"countryCode":42,"cosmosGeoPoint":72,"geoPoint":76,"contacts":77},"Philadelphia","Pennsylvania","19104",{"type":44,"coordinates":73},[74,75],-75.16362,39.95238,{"lat":75,"lon":74},[78,82],{"name":79,"role":33,"phone":80,"phoneExt":10,"email":81},"Elizabeth Norton","267-438-2709","elizabeth.norton@pennmedicine.upenn.edu",{"name":25,"role":23,"phone":10,"phoneExt":10,"email":10},{"type":23,"investigatorFullName":84,"investigatorTitle":85,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Amy Miyoshi Valent","Principal Investigator",[87,90,91],{"name":88,"class":89},"DexCom, Inc.","INDUSTRY",{"name":26,"class":6},{"name":29,"class":6},"100620389","stelo-real-time-continuous-glucose-monitor-use-postpartum-for-lifelong-optimal-wellness-100620389",false,"NCT07356986","Stelo Real-time Continuous Glucose Monitor Use Postpartum for Lifelong Optimal Wellness","STELO-GLOW","Inclusion Criteria:\n\n* Gestational Diabetes Mellitus (GDM) diagnosis by 1- or 2-step Oral Glucose Tolerance Test (OGTT) during pregnancy or \\>= 200 mg following any glucose challenge (50g, 75g, 100g)\n* Has a smart phone compatible to support Dexcom Stelo app\n* Able to read, write, and understand English\n* Meet Stelo Glucose Biosensor Indications for Use (IFU) per approved commercial labeling\n* Willing to follow all study procedures\n\nExclusion Criteria:\n\n* Greater than 6 weeks and 6 days postpartum at enrollment\n* Preexisting Type 1 Diabetes (T1D) or Type 2 Diabetes (T2D)\n* End-stage renal failure (on dialysis)\n* Heart failure\n* Other uncontrolled high-risk condition as determined exclusionary by site investigators\n* Extensive skin changes\u002Fdiseases that preclude wearing the required system on normal skin (e.g. extensive psoriasis, recent burns or severe sunburn, extensive eczema, extensive scarring, extensive tattoos, dermatitis herpetiformis) at the proposed wear sites\n* Known severe allergy to medical-grade adhesives\n* Any condition that, in the opinion of the investigator, would interfere with their participation in the trial\n* Obesity surgery\n* Insulin use prior to discharge home from the delivery admission\n* Current participation in another postpartum Continuous Glucose Monitoring (CGM) or lifestyle intervention trial","FEMALE","18 Years",{"count":102,"type":103},50,"ESTIMATED","OBSERVATIONAL","The purpose of this prospective observational study is to gather exploratory and practical use data of the Dexcom Stelo Glucose Biosensing System (Stelo), an over-the-counter (OTC) real-time Continuous Glucose Monitoring (CGM) system among patients with Gestational Diabetes Mellitus (GDM) in their most recent pregnancy.",[107,108],"Gestational Diabetes","Postpartum",[110,111],"Continuous Glucose Monitoring","Postpartum Glucose Management","NOT_YET_RECRUITING","2026-01-12",{"date":115,"type":116},"2026-01-21","ACTUAL",{"date":118,"type":103},"2026-01",{"date":120,"type":103},"2027-12",{"name":5,"class":6},3]